Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

1.

Seven-year Observational Study on the Association between Glycemic Control and the New Onset of Macroangiopathy in Japanese Subjects with Type 2 Diabetes.

Kimura T, Kaneto H, Kanda-Kimura Y, Shimoda M, Kamei S, Anno T, Kawasaki F, Hashiramoto M, Matsuki M, Mune T, Kaku K.

Intern Med. 2016;55(11):1419-24. doi: 10.2169/internalmedicine.55.4952. Epub 2016 Jun 1.

2.

Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study).

Tawaramoto K, Kaneto H, Hashiramoto M, Kawasaki F, Tatsumi F, Shimoda M, Kamei S, Matsuki M, Mune T, Kaku K.

Diabetol Metab Syndr. 2015 Sep 17;7:80. doi: 10.1186/s13098-015-0073-9. eCollection 2015.

3.

Combination of DPP-4 inhibitor and PPARγ agonist exerts protective effects on pancreatic β-cells in diabetic db/db mice through the augmentation of IRS-2 expression.

Hirukawa H, Kaneto H, Shimoda M, Kimura T, Okauchi S, Obata A, Kohara K, Hamamoto S, Tawaramoto K, Hashiramoto M, Kaku K.

Mol Cell Endocrinol. 2015 Sep 15;413:49-60. doi: 10.1016/j.mce.2015.06.010. Epub 2015 Jun 25.

PMID:
26116826
4.

Anti-hypertensive azelnidipine preserves insulin signaling and glucose uptake against oxidative stress in 3T3-L1 adipocytes.

Tatsumi F, Kaneto H, Hashiramoto M, Tawaramoto K, Obata A, Kimura T, Shimoda M, Hamamoto S, Kanda-Kimura Y, Kamei S, Mune T, Matsuda M, Kaku K.

Endocr J. 2015;62(8):741-7. doi: 10.1507/endocrj.EJ15-0273. Epub 2015 Jul 13.

5.

Low bilirubin levels are an independent risk factor for diabetic retinopathy and nephropathy in Japanese patients with type 2 diabetes.

Hamamoto S, Kaneto H, Kamei S, Shimoda M, Tawaramoto K, Kanda-Kimura Y, Kawasaki F, Hashiramoto M, Matsuki M, Mune T, Kaku K.

Diabetes Metab. 2015 Nov;41(5):429-31. doi: 10.1016/j.diabet.2015.05.003. Epub 2015 Jun 6. No abstract available.

PMID:
26054296
6.

Case of newly onset type 1 diabetes after highly active antiretroviral therapy against HIV infection.

Kamei S, Kaneto H, Hashiramoto M, Hisano Y, Tanabe A, Shimoda M, Tawaramoto K, Anno T, Mune T, Matsuki M, Kaku K.

J Diabetes Investig. 2015 May;6(3):367-8. doi: 10.1111/jdi.12286. Epub 2015 Apr 23. No abstract available.

7.

Dietary restriction preserves the mass and function of pancreatic β cells via cell kinetic regulation and suppression of oxidative/ER stress in diabetic mice.

Kanda Y, Hashiramoto M, Shimoda M, Hamamoto S, Tawaramoto K, Kimura T, Hirukawa H, Nakashima K, Kaku K.

J Nutr Biochem. 2015 Mar;26(3):219-26. doi: 10.1016/j.jnutbio.2014.10.007. Epub 2014 Nov 15.

PMID:
25488546
8.

Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes.

Kimura T, Kaneto H, Shimoda M, Hirukawa H, Okauchi S, Kohara K, Hamamoto S, Tawaramoto K, Hashiramoto M, Kaku K.

Mol Cell Endocrinol. 2015 Jan 15;400:78-89. doi: 10.1016/j.mce.2014.11.018. Epub 2014 Nov 24.

9.

Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus.

Tatsumi F, Hashiramoto M, Hirukawa H, Kimura T, Shimoda M, Tawaramoto K, Kanda-Kimura Y, Anno T, Kawasaki F, Mune T, Matsuki M, Kaku K.

Diabetes Res Clin Pract. 2013 Jul;101(1):35-44. doi: 10.1016/j.diabres.2013.04.007. Epub 2013 May 24.

PMID:
23711593
10.

Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness--Justification for Atherosclerosis Regression Treatment (JART) extension study.

Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, Kurabayashi M, Masuda I, Sakuma I, Yamazaki T, Yokoi H, Yoshida M; Justification For Atherosclerosis Regression Treatment (JART) Investigators.

Circ J. 2013;77(6):1526-33. Epub 2013 Mar 14.

11.

Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study.

Yamazaki T, Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, Kurabayashi M, Masuda I, Sakuma I, Yokoi H, Yoshida M; Justification for Atherosclerosis Regression Treatment (JART) Investigators.

Int Heart J. 2013;54(1):33-9. Erratum in: Int Heart J. 2013;54(4):246.

12.

Sirtuin 1 as a key player of 'metabolic memory'.

Hashiramoto M, Kaku K.

J Diabetes Investig. 2013 Jan 29;4(1):34-6. doi: 10.1111/j.2040-1124.2012.00244.x. Epub 2012 Sep 20. No abstract available.

13.

[Hypoglycemia].

Hashiramoto M, Kaku K.

Nihon Rinsho. 2012 Aug;70 Suppl 6:702-9. Japanese. No abstract available.

PMID:
23156601
14.

Vildagliptin preserves the mass and function of pancreatic β cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes.

Hamamoto S, Kanda Y, Shimoda M, Tatsumi F, Kohara K, Tawaramoto K, Hashiramoto M, Kaku K.

Diabetes Obes Metab. 2013 Feb;15(2):153-63. doi: 10.1111/dom.12005. Epub 2012 Sep 25.

15.

[Sulfonylurea-pioglitazone combination agent].

Hashiramoto M, Kaku K.

Nihon Rinsho. 2012 May;70 Suppl 3:633-41. Japanese. No abstract available.

PMID:
22768590
16.

International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values.

Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H; Committee on the Standardization of Diabetes Mellitus‐Related Laboratory Testing of Japan Diabetes Society.

J Diabetes Investig. 2012 Feb 20;3(1):39-40. doi: 10.1111/j.2040-1124.2012.00207.x. No abstract available.

17.

Ablation of 3-phosphoinositide-dependent protein kinase 1 (PDK1) in vascular endothelial cells enhances insulin sensitivity by reducing visceral fat and suppressing angiogenesis.

Tawaramoto K, Kotani K, Hashiramoto M, Kanda Y, Nagare T, Sakaue H, Ogawa W, Emoto N, Yanagisawa M, Noda T, Kasuga M, Kaku K.

Mol Endocrinol. 2012 Jan;26(1):95-109. doi: 10.1210/me.2010-0412. Epub 2011 Nov 22.

PMID:
22108800
18.

Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study.

Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, Kurabayashi M, Masuda I, Sakuma I, Yamazaki T, Yokoi H, Yoshida M; Justification for Atherosclerosis Regression Treatment (JART) Investigators.

Circ J. 2012;76(1):221-9. Epub 2011 Nov 16. Erratum in: Circ J. 2012;76(2):522. Fujii, Katsuhito [corrected to Fujiu, Katsuhito]; Hiroi, Yukio [added]; Konishi, Hakuoh [added]; Matsuki, Michihiro [added]; Matsuoka, Takaaki [added]; Okauchi, Seizo [added]; Ozaki, Akihiko [added];Satoi, Satoshi [added]; Sawaki, Daigo [added]; Takahashi, Maiko [corrected to Takahashi, Makio].

19.

Thiazolidinediones and bone fractures.

Kaku K, Hashiramoto M.

J Diabetes Investig. 2011 Oct 7;2(5):354-5. doi: 10.1111/j.2040-1124.2011.00142.x. No abstract available.

20.

The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes.

Shimoda M, Kanda Y, Hamamoto S, Tawaramoto K, Hashiramoto M, Matsuki M, Kaku K.

Diabetologia. 2011 May;54(5):1098-108. doi: 10.1007/s00125-011-2069-9. Epub 2011 Feb 22.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk